Halozyme Therapeutics has delivered impressive revenue growth and free cash flow margins, but its adjusted operating margin has contracted significantly over the past five years. The company's annualized revenue growth over the last five years was 35.4%, and its free cash flow margin averaged 46.2% over the same period. However, its adjusted operating margin decreased by 35.1 percentage points over the last five years, with the trailing 12-month figure at 33.9%. The stock currently trades at $78.57 per share, or 9.1 times forward earnings.
Halozyme Therapeutics IncRevenue growth and FCF margins are positive, but shrinking operating margins and forward P/E of 9.1 create mixed signals.